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Abstract
Conventional fresh platelets stored at 20–24°C have a short shelf life, at most 7 days. Their 
main disadvantage is logistics as it is more difficult. This limitation is especially problem-
atic for emergency and intensive care departments for managing massive bleeding.  The 
early and aggressive use of blood products for massive hemorrhage may correct coagu-
lopathy, control bleeding, and improve outcomes. The timely availability of platelets at 
the shortest time after the injury is often problematic.  Many hospitals cannot afford to 
have platelets permanently in stock because of its short shelf life. Cryopreservation and 
storage of frozen platelets may significantly prolong their shelf life. Thus, frozen platelets 
provide long-term accessibility in situations where fresh products are not available. The 
most widely used method for the platelets cryopreservation is freezing at 5–6% DMSO at 
−80°C. The production of cryopreserved platelets is not technologically demanding, they 
can be easily thawed and reconstituted. Frozen platelets are an alternative blood product 
for urgent orders in connection with heavy bleeding. They are cost-effective functional 
platelets product for the management of bleeding and should be considered for wider 
use in clinical practice, such as autologous platelets, rare or HLA/HPA compatible plate-
lets and  platelets for non-transfusion use.
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1. Introduction
Various methods of cryopreservation of blood cells are generally known and have been used 
for a long time. The storage of blood in the frozen state presented one of the alternative ways 
of storing blood components; this possibility was intensively explored in the 1950s and 1960s, 
when the shelf life of nonfrozen red blood cells did not exceed 21 days at those times. This 
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time limitation significantly reduced flexibility of usage of RBC products and contributed to 
their dramatically high and wasteful expiration reaching up to 30%. The short shelf life of the 
RBCs resulted in the transfusion services not being able to meet demands of quickly evolv-
ing surgical disciplines, particularly cardiovascular surgery and radical surgical oncology. In 
military and emergency healthcare, utilization of these 3-week products as a way of creating 
blood supplies was even more complicated, almost unthinkable. The storage of frozen red 
blood cells therefore presented a great prospect [1].
Nevertheless, some areas with a need to long-term storage of the blood cells still 
remained—for example, being the military transfusion, emergency transfusion service, 
storage of rare blood cells, or special autologous transfusion programs. Blood substitution 
and blood supply are permanent strategic and logistic problems of the military medical 
services across the world arising from the blood, has a limited shelf life and need the 
special transport and use conditions. The same problem must solve the national healthcare 
authorities in programs of the national blood crisis policy, where to get a huge amount 
of blood supply any time at any place in the case of disaster, terrorist attack, and war. 
The therapeutic problems in immunohematology cases can solve by stock of rare blood, 
storage of autologous blood for patients with rare erythrocyte or platelets antigens, and 
storage of autologous blood for patients with red blood cell alloantibodies or HLA/HPA 
platelets refractoriness with no chance to use common blood. All mentioned demands 
highly correspond with stock of frozen blood. New global security risks exalt this problem 
to all-society relevancy [1].
If the short storage time and shelf life can be problematic at fresh red blood cells, this dis-
advantage is greatly enhanced at standard platelet products. Fresh platelet, stored at a 
temperature of 20–24°C, have shelf life of 5–7 days. This excludes the production of larger 
supplies and makes their production, distribution, and use, logistically more difficult. This 
is particularly limiting for trauma centers, urgent hospital admissions, and intensive care 
units dealing with massive bleeding. Extremely difficult is the implementation of platelet 
transfusion in war medicine, remote areas, and pre-hospital care. Uncontrollable bleeding 
is the second leading cause of death in trauma patients. In battlefield casualties with severe 
blood loss, platelets are often deficient because of blood loss and because the platelets get 
consumed during blood clotting.
In many instances, frozen platelets are given prophylactically and autologous or HLA/HPA 
compatible frozen platelet transfusions have become an important part of the supportive care 
of leukemic patients at this institution during maintenance and reinduction therapy, when 
alloimmunization is frequently present.
2. Methods of cryopreservation of blood cells
The primary role of cryopreservation is the long-term preservation of cells and tissues while at 
the same time protecting them from the undesirable effects of frost. Already in 1866, Pouchet 
first described that frozen erythrocytes are destroyed after thawing [2].
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During the changing process of aqueous solutions into solid state, it is water that changes 
its state of matter first. Water crystals are created from pure water, while the space between 
them is filled with concentrated electrolyte. This leads to cellular dehydration and to the pH 
change and those mechanisms destroy cell membrane before mechanical injury is caused by 
ice crystals [1, 3, 4].
Protection of cells from freezing is achieved by adding cryoprotective substances. Since 
these cryoprotectants usually cause a significant increase in osmolality, it is neverthe-
less necessary to have all the procedures monitored, and to have osmotic changes under 
control, in order to avoid an irreversible damage to cellular structures and membranes 
caused by them [1].
Mainly, intracellular (penetrative) cryoprotectants, as glycerol and dimethyl sulfoxide 
(DMSO), are used for the cryopreservation of blood cells. These substances penetrate the 
cellular membrane and do not present any toxic danger to the cell when in low concentra-
tion. Glycerol is used for red blood cells cryopreservation and DMSO for platelets freezing. 
The mechanism of the effect of penetrative cryoprotectants has not been fully clarified yet. 
Initially, the damage of cells was associated with the effect of ice crystals only. Cryoprotective 
substances, nevertheless, besides limiting the creation or frozen crystals, also modify these 
crystals’ shape and size, and by changing their ionic ratio intracellularly and extracellularly; 
they also eliminate the damage caused by osmotic shock, which otherwise occurs during 
freezing. During the freezing process, penetrative cryoprotectants increase output of intracel-
lular water, maintaining the osmotic balance in a partially frozen extracellular solution in this 
way. It results in not only reducing the cells’ volume but also in the reduction of the osmotic 
load [1, 5–19].
Extracellular (nonpenetrative) cryoprotectants are macromolecular substances and due to their 
molecular mass, they do not penetrate cellular membrane and are mostly used for rapid and 
ultra-rapid freezing. The mechanism of the nonpenetrative cryoprotectants effect lies in their 
ability to stabilize cellular membrane and also in so-called vitrification. When there is water 
(with temperature below 0°C) turning into ice, nonpenetrative cryoprotectants remain outside 
the cells, where they secure the creation interspaces between cellular membrane and extracel-
lular environment. Electrolytes segregated from freezing solutions are being concentrated in 
these interspaces [1].
This cryoprotectans, previously rarely used, are no longer used for cryopreservation of 
blood [20–24].
3. Cryopreservation of platelets
3.1. Methods of platelets cryopreservation
Platelets may be frozen using various types of cryoprotectants: intracellular (DMSO and 
glycerol) or extracellular (HES and dextran). HES and dextran were found to be poor 
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cryoprotectives, PLTs cryopreserved in glycerol gave lower yields and poor in vitro viabil-
ity compared with those cryopreserved in DMSO, which is most suitable cryoprotectant for 
platelets.
Djerassi et al. [25] were the first to report on the use of 5% dimethyl sulfoxide and cooling 
at 1°C/min for successful cryopreservation and transfusion of human platelets. To avoid the 
effects related to the cryoprotectant itself (e.g., nausea, vomiting, local vasospasm, garlic-
like taste, and body odor), Lundberg et al. [26] have introduced a post-thaw washing step. 
A method used by Schiffer et al. [27] has become the “standard” method for this purpose.
In 1956, Klein et al. reported the use of previously frozen platelets in an actively bleeding 
thrombocytopenic patient and ever since numerous studies have been reported on both the 
in vitro and in vivo efficacies of cryopreserved platelets [28]. Since Schiffer et al.’s 1976 study 
on the use of autologous platelets for the treatment of patients with leukemia, relevant stud-
ies until 1990s showed that the platelets were damaged to a significant extent by the freezing 
process that decreased their efficacy when compared to fresh platelets [27]. These results were 
supported by other in vitro studies that assessed the platelets’ primary hemostatic functions. 
It has been demonstrated that the in vivo hemostatic functions of cryopreserved APCs were 
superior to the fresh preserved platelets [29] and reported the procoagulant changes in the 
frozen-treated platelet membrane surfaces [30].
The most widely used method for the platelets cryopreservation is freezing at 5–6% DMSO 
concentration at −80°C, with their storage at −65°C and lower. The method of platelet cryo-
preservation using DMSO was developed in the 1970s by Robert Valeri with the support of 
the US Navy’s research program as a possible substitute for native platelets for transfusion 
therapy for wounded service personnel during military operations [19, 29, 31]. In the origi-
nal method, the DMSO and the supernatant needed to be washed out upon thawing, mak-
ing the method arduous for use in field hospitals. Over time, the procedure was adjusted to 
remove the excess DMSO and supernatant prior to freezing [29, 32, 33]. The method is simple, 
inexpensive, and requires no special equipment. For transport over long distances, transport 
containers filled with dry ice are used. Alternatively, it is possible to use transport active freez-
ers providing a temperature of <−65°C. As the storage temperature of DMSO-cryopreserved 
platelets ranges from −80 to −65°C, the use of liquid nitrogen (or its fumes) is not necessary, 
and mechanical deep freezers can be used for storage instead. After thawing, the platelets are 
suspended in thawed plasma and there is no need to wash out the cryoprotectant. Original 
method can be modified by resuspension of thawed platelets in saline (0.9% NaCl) or plasma 
additive solution (PAS).
The procedures for cryopreservation of platelets according to the modified Valeri method 
are as follows:
I. To the collecting container with standard unit with apheresis or buffy-coat pooled plate-
lets, preferably leucodepleted, with >280 × 109 PLT/unit and in the original donor plasma, 
is added 75 ml 25% solution DMSO in 0.9% NaCl resulting to 5–7% final DMSO concen-
tration in platelet unit (Figure 1).
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II. The container with PLTs + DMSO is connected with smaller container (using sterile con-
nection device), where platelets will freeze (Figure 2).
III. Centrifugation 20 min, use soft spin (Figure 3).
IV. Gently removing of supernatant using the manual extractor and using visual control, 
tube sealing and labeling. The final product has 13–15 ml (Figures 4 and 5).
V. Freezing in cartoon box at −80°C, storage at −65 to −80°C (Figures 6 and 7).
The procedures for thawing the platelets according to the modified Valeri method are as follows:
I. One unit of frozen platelets and one unit of frozen plasma are thawed to 34–36°C. It 
is recommended to check the concordance of temperatures of both products at surface 
temperature, using contactless infrared thermometer (Figures 8–11).
II. The thawed platelets are gently “spreading” using a gauze with emphasis to flatten of 
potentially aggregates (Figure 12).
III. Connecting container with thawed platelets and container with thawed plasma, using 
sterile connection device. The plasma is transferred into the platelets by gentle stirring. 
Transferring the contents of the bags back and forth (three times) ensures a perfect mix of 
the products and a homogeneous suspension is obtained (Figures 13 and 14).
Note, the visual control is focused mainly on the presence/absence of aggregates. In 
thawed, previously frozen platelets, usually is not seen swirling phenomenon. The 
explanation is, that thawed thrombocytes are activated, altered in shape, with numbers 
of pseudopodia on the surface that make this optical phenomenon impossible.
IV. The final product (in the original platelet container) is detached from the plasma con-
tainer, labeled and released for transfusion. The thawing and reconstitution does not 
exceed 30 min.
V. If plasma is used for reconstitution, as described above, the type AB plasma mixed with type 
O platelets is used. However, for reconstitution, other solutions can be used, PAS or saline.
VI. The shelf life of thawed and reconstituted platelets depends on the technical procedure 
of adding DMSO. It is usually 6 hours because of a non-sterile connection of a glass bottle 
with DMSO.
3.2. Features and quality of cryopreserved platelets
Platelets stored frozen are efficient in primary hemostasis after thawing. They efficiently con-
tribute to stop bleeding as a part of complex transfusion therapy or damage control resuscita-
tion in polytrauma patients and patients with massive bleeding. Some studies confirm that 
after reconstitution, the life span of platelets cryopreserved using DMSO in human circulation 
is comparable to native platelets in vitro [29, 34–37].
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The most widely used method is the reconstitution of cryopreserved platelets in thawed 
plasma, but there seems to be no significant difference between platelets reconstituted in 
other solutions, such as saline or PAS [29, 38, 39].
Figure 2. Sterile connection of the container with PLTs contained DMSO to container for freeze.
Figure 1. Add DMSO to collected fresh platelets.
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Although the platelets stored by cryopreservation are efficient in hemostasis, they are 
affected by a number of functional defects during storage and preparation for transfu-
sion. The process of freezing and thawing causes changes in platelet morphology and 
affects their function. Approximately 15% of cryopreserved platelets lost surface-bound 
GPIb, while there was no measurable loss of GPIIB/IIIa during cryopreservation. The 
Figure 4. Removal of supernatant from platelets before freezing using the manual extractor.
Figure 3. A large volume centrifuge for platelets centrifugation.
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cryopreserved platelets also showed a significant decrease in aggregation to ristocetin, 
but no loss of response to the stronger agonist, thrombin. Even though these defects are 
of a minor clinical relevance and the cryopreserved platelets were shown to be safe and 
Figure 6. Platelets before freezing.
Figure 5. Removed supernatant (left) and the final platelets product prepared for freezing (right).
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effective for the treatment of abnormal bleeding, it is still necessary to reckon with these 
changes [22, 40, 41].
In cytometric observation, the frozen platelets contain about 85% of the particles in the mic-
roparticle area and only about 15% of the particles in the platelets region. For fresh platelets, 
this ratio is about 20% of microparticles and 80% of platelets. The question is to what extent 
higher amounts of microparticles are responsible for the observed higher hemostatic efficacy 
Figure 7. An example of −80°C portable freezing box.
Figure 8. Frozen platelets.
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of cryopreserved platelets. Additionally, cryopreserved platelets are considerably smaller 
than fresh platelets and have a lower perpendicular light scattering, reflecting not only their 
smaller size but also their spherical shape. Unlike the fresh platelets, frozen platelets are 
highly positive for Annexin V binding. This may contribute to their higher thrombin genera-
tion potential and lower circulating ability [42].
Platelet cryopreservation is associated with the release of platelet membrane particles and 
thrombin generation. The microparticles formed by cryopreservation carry phosphati-
dylserine on their surfaces and thus are phenotypically different from those found before 
freezing. Cryopreserved platelets have greater endogenous thrombin potential than fresh 
platelets [43].
Figure 9. Frozen plasma.
Figure 10. Plasma/platelets thawer.
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This confirms the fact that platelet activation release of substances that potentiate the growth 
of thrombin generation occurs during cryopreservation and subsequent reconstitution. This 
is a set of reasons why the frozen platelets exhibit increased coagulation activity leading to 
faster clot formation with a concurrent decrease in clot strength. Such fact is confirmed by the 
thromboelastography measurements. The TEG curves evidently show a decrease in coagula-
tion initiation time, that is, higher coagulation activity and faster clot formation (wider angle α), 
and a reduced maximum clot strength (MA), which is, however, still sufficient for initial 
coagulation [44–46]. The coagulation activity is further increased by reconstitution in fro-
zen plasma. Platelets resuspended in such a way are more efficiently coagulative than, for 
example, platelets resuspended in additive solution.
Some observations by electron microscopy show plasma membrane disruption and vesicula-
tion in 60% of thawed platelets. More than half of cryopreserved platelets exhibit signs of 
platelet membrane damage with a significant increase in its fluidity, induced by 6% DMSO 
alone and by the freezing and thawing process.
To speed up cryopreserved platelet reconstitution in plasma, it is possible to use plasma stored 
at a temperature of 4°C, meaning that the products can then be used within 15 min. However, 
for patients requiring the platelets for an indication other than hemostasis, resuspension in 
additive solution may be a suitable choice.
Figure 11. Temperature check.
Figure 12. Spreading of thawed platelets.
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The administration of cryopreserved platelets usually is not followed by any increase in blood 
platelet count, as in the case for fresh platelets and corrected count increments for platelets 
(CCI) is hard to use for evaluation of treatment effectiveness. This may be due to several causes. 
First is the broken structure and shape of thawed platelets associated with the higher amount 
of phosphatidylserine on their surface, which apparently contributes to the lower survival time 
Figure 13. Sterile connection of thawed platelets with thawed plasma.
Figure 14. Transfer thawed plasma to thawed platelets.
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in circulation and lead to their immediate consumption in hemostasis. Another reason may 
be their more difficult resolution for the blood count analyzers. In the group of patients trans-
fused with fresh platelets, a significantly higher platelet count was found in peripheral blood 
when compared to the patients transfused with cryopreserved platelets. Other laboratory and 
clinical parameters (clinical efficacy) are comparable. However, this is one of the reasons why 
cryopreserved platelets are recommended mainly for substitution in conditions associated 
with severe bleeding, and less for prophylactic treatment of hematological thrombocytopenia.
It is also necessary to keep in mind the differences associated with cryopreserved platelets, 
such as membrane-bound coagulation factors V and X, increased formation of thromboxane 
B2, and the significant presence of the released microparticles. However, these observations are 
unlikely to have great clinical relevance for the use of cryopreserved platelets in the treatment 
of massive bleeding, particularly in terms of any possible influence on their coagulation activity 
[47]. Similarly, clinical efficacy is not influenced by decreased platelet counts in the preparation 
or lower recovery rate after thawing. These are adequately compensated by a comparable life 
span in the patient’s circulation, as shown in healthy volunteer studies published previously.
In the studies published so far, no severe reactions were reported following administration of 
frozen platelets and this was confirmed by our observation. Furthermore, no negative effect of 
increased coagulation activity of the cryopreserved platelets was observed [36, 48].
3.3. Use and perspectives of cryopreserved platelets
Cryopreservation and storage of frozen platelets may significantly (or unlimitedly) prolong 
their shelf life. Thus, frozen platelets provide long-term accessibility in situations where fresh 
and native products are not available and there is no way of obtaining them. The production 
of cryopreserved platelets is not technologically demanding, and furthermore, they can be 
easily thawed and reconstituted.
Early massive and complex transfusion therapy, excluding erythrocyte substitution, contrib-
utes significantly to coagulopathy correction and the alleviation of bleeding. The rapid admin-
istration of the whole spectrum of transfusion products is proven to have a positive impact on 
patient survival. Therefore, most current transfusion protocols and hemostatic resuscitation 
procedures are based on the co-administration of erythrocytes and plasma, supplemented 
with platelet transfusion [29, 49].
Platelet availability for the timely application of a modern massive transfusion protocol dur-
ing the first “golden hour” following the onset of bleeding is often problematic. Furthermore, 
most hospitals cannot afford to have native platelets permanently available due to their short 
expiration and high price. Even university hospitals and large trauma centers may experience 
a limited availability of platelets in cases of urgent need for large quantities. Ensuring the 
availability of platelets in field military hospitals, namely in current international military 
operations, is even more problematic.
Although the given thawing and reconstitution procedure describes the use of a sterile bag 
tubing welder when connecting the platelet and plasma bags, the use of a sterile connection 
device is not necessary. In blood banks that do not have this technology, it is advantageous to 
connect the bags using simple tubing with spikes at both ends.
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The relatively short shelf life of cryopreserved platelets (2 years) as blood product is based on the 
European directive and has no real evidential basis. The data from a study conducted in a labo-
ratory at the Militaire Bloedbank in Leiden, the Netherlands, are currently being processed [50]. 
According to the preliminary information, these data support the possibility of extending the shelf 
life to at least 4 years. The preparation shelf life of 6 h, after thawing and reconstitution, is based on 
the fact that the process of adding the DMSO before freezing does not take place in a completely 
closed system and at the same time, it allows the use of tubing to add the resuspension media. If the 
DMSO was commercially manufactured in a plastic bag as a medical device using a sterile welder, 
it would be possible to extend the shelf life of the cryopreserved platelets even after reconstitution.
In recent years, there has been a relatively large renegotiation of interest in cryopreserved 
platelets as a promising blood product, which is being used, tested, and validated in a number 
of countries and institutions.
Therefore, cryopreserved platelets constitute a suitable alternative, which has been used by 
the Dutch Military Health Service and other countries for some time [4, 50–54]. The easy 
availability, compatibility, safety, and efficacy of the cryopreserved products significantly 
improved survival rates of patients with war injuries treated during international missions 
at Dutch army field hospitals in 2001–2012. Another advantage is the possibility of storing 
HLA-/HPA-matched platelets and rare platelets, as well as autologous platelets.
3.3.1. A brief overview of the use of cryopreserved platelets in the world
See Refs. [48, 51–53, 55–57].
3.3.1.1. Australia
Production:
Yes, for the military and for clinical civil studies.
Use:
In civil society so far only in clinical trials.
Method:
In 6% DMSO, 24–48 h after storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution at 30°C, exp. 6 h.
Advantages:
Long service life.
Decreased expiration and thrombo-thawing on the patient.
Increased procoagulant activity—an advantage for pac. with severe bleeding.
3.3.1.2. Belgium
Production:
Yes, for the army.
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Use:
In civilian, not in a prospective military operation.
Method:
In 6% DMSO.
Storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution, exp. 6 h.
Advantages:
Long shelf life, protrobotic potential.
3.3.1.3. Brazil
Production:





Storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution, exp. 4 h.
Advantages:





Yes, so far Military University Hospital Prague, prospective in trauma centers.
Method:
In 6% DMSO, within 2 h of collection.
Storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution at 32°C, exp. 6 h.
Advantages:
Immediate availability, procoagulant activity—suitable for severe bleeding.
Stock of platelets for field military medical service.







Yes: rare HPA/HLA platelets, severe bleeding.
Method:
In 5% DMSO.
Storage at −65 to −90°C, exp. 2 years/−180°C, exp. 3 years.
Plasma reconstitution at 32°C, exp. 6 h.
Advantages:
Platelets availability when native platelets are not available, platelets used for field military 
care and in remote areas.
3.3.1.6. Canada
Production:









Procoagulant activity—suitable for severe bleeding.





Heavy bleeding (obstetrical bleeding), autologous platelets.
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Method—considered:
In 5–6% DMSO.







Yes: 11–13,000 T.D./year (10–12% of total platelet consumption).
If there are no native, special indications: neonates and intranasal transfusions at immuno-
logical thrombocytopenia, HLA/HPA rare platelets.
Method:
In 5% DMSO, within 24 h of collection.
Storage at −65 to −90°C, exp. 1 year/−140°C, exp. 2 years.
Reconstitution in 0.9% NaCl, exp. 2 h at 20–24°C.
Advantages:




Yes—only for research yet.
Use:
No, they are looking forward.
Method:
In 6% DMSO, from BC.
Storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution at 32°C, exp. 4 h.










Yes, HLA typed platelets.
Method:
In 6% DMSO.
Storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution at 32°C, exp. 4 h.
Advantages:
Providing HLA typified thrombocytes.
3.3.1.11. The Netherlands
Production:
Yes, only in military blood bank.
Use:
Yes, only in the field military health service.
Method:
In 6% DMSO, from apheresis, 24 h after collection.
Storage at −65 to −90°C, exp. 4 years.
Plasma reconstitution at 32°C, exp. 6 h.
Advantages:
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Method:
In 5% DMSO.
Storage at −65 to −80°C, exp. 2 years.
Plasma reconstitution.
Advantages:





The strategic location of Turkey mandates governmental medical organizations in estab-
lishing frozen platelet and erythrocyte stocks.
Method:
In 4–6% DMSO.
Storage at −65 to −80°C, exp. 2 years.
Plasma reconstitution/0.9% NaCl.
Advantages:
Maintain a stock of platelets, military use.
3.3.1.14. USA
Production:
Yes, so far only for studies, in perspective after FDA approval.
Use:
Not yet, only in studies.
Method:
In 4–6% DMSO.
Storage at −65 to −90°C, exp. 2 years.
Plasma reconstitution/0.9% NaCl.
Advantages:
Maintain a stock of platelets and stock of HLA-typed platelets, military use.




The cryopreservation of blood is a method, which solves various problems in blood transfu-
sion service. The main application is in military medicine and blood crisis policy, but also in 
special transfusiology fields, such as the storage of rare red blood cells and long-term stor-
age of autologous blood. Due to modern procedures, which allow for prolonged shelf time 
after thawing and reconstitution of frozen blood, the use of frozen blood is now more flex-
ible and less limited. Cryopreserved blood products are fully in comliance with European 
legislation [1].
Cryopreserved platelets have all the necessary prerequisites to constitute a product suit-
able for a possible wider application. Due to the extended shelf life, it is possible to cre-
ate sufficient supplies of these transfusion products without a substantial cost increase. 
Cryopreserved platelets are suitable for both civilian and military use, particularly for the 
treatment of acute conditions associated with massive bleeding, when no permanent or 
sufficient supply of fresh platelets is available. Cryopreserved platelets act as a substitute 
for human platelets by helping the blood clotting mechanism in patients, who have a 
deficiency of platelets. Thawing and reconstitution is a simple procedure that takes no 
more than 30 min.
Cryopreserved platelets may find use in other indications, such as the autologous products, 
rare or HLA/HPA compatible platelets or in a wide range of nontransfusion applications. Due 
to their low production cost, the use of cryopreserved platelets does not represent a signifi-
cant increase in the cost of transfusion therapy. Our work and previous studies suggest that 
cryopreserved platelets are efficient, effective, and safe.
Despite the stated advantages, the use of cryopreserved platelets in clinical practice has hith-
erto been rather limited and scarce. Their wider application is hindered by relatively little 
data on their in vitro attributes or on the comparison with the attributes of fresh platelets, and 
the complete absence of clinical studies evaluating their efficacy in vivo.
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